David A. Roth, Ph.D. work email
- Valid
- Valid
- Valid
- Valid
David A. Roth, Ph.D. personal email
- Valid
David A. Roth, Ph.D. phone numbers
Recognized executive level scientific and management experience in drug development and R&D environments in the biotechnology, pharmaceutical, and industrial enzyme industries. Extensive experience in a variety of animal models and cell- and molecular biology-based R&D strategies with business and commercial development experience. Areas of expertise: • Research Operations• Pre-clinical Product Development• Protein, Peptide and Gene Therapeutics• Protein- and DNA-based Vaccine and Diagnostics Development• Biologics Discovery and Development• Strategic Alliances and Business Development• Grants and Contracts: Successful SBIR and STTR awards in multiple start-up biotechnology companies from multiple agencies (NIH, DoD, DARPA, NMRC, DoE).• Life Sciences Portfolio Management• Experienced and effective manager of Ph.D. level scientists and research associates.• Strong analytical, communication, project management and budgeting skills.Specialties: Research Ops, Preclinical Dev• Biologics and Technology Development• Strategic alliances, collaborative R&D projects • Contracts and grantsBusiness Development• Strategic business planning/development• Technology evaluation, due diligence• Licensing• Alliances and partnershipsIP Capture & Expansion, Asset Management • New inventions: patents, trademarks• Identification of IP opps, freedom to operate• Strategic portfolio building• Scientific and IP liaison
Multimeric Biotherapeutics, Inc.
-
Chief Operating OfficerMultimeric Biotherapeutics, Inc. Oct 2007 - PresentLa Jolla, CaI am COO and co-founder of MultimericBio with my partners, Richard S. Kornbluth, MD, PhD - President and CSO, and Marc Hertz, PhD - Chairman of the Board, based in La Jolla, CA. We are a blossoming biotechnology company with worldwide rights to licensed patents covering all of the Tumor Necrosis Factor (TNF) SuperFamily ligands (CD40 Ligand is our lead product - the multimeric/many trimer form is called Ultra-CD40L) from UCSD that enables a powerful platform technology for clinical development of cancer immunotherapies and robust adjuvants for infectious disease vaccines. We have multiple active USG grants and contracts, extensive partnerships in biotech and pharma, and are actively seeking private funding from VC and private investor sources.
-
Science Department ChairSage Ridge School Aug 2018 - Jul 2023Reno, Nevada, United StatesBiology, Human Anatomy and Physiology -
Department Chair: Science, Math And Engineering; Director Of Steam ProgramWasatch Academy Aug 2011 - Jun 2018Mount Pleasant, UtahWasatch Academy is an international (41 countries, 28 states), college prep boarding school for 340 students located in the Sanpete Valley of central Utah. We deliver high quality education and student services via Competency-Based Learning, Outdoor/Experiential and Expeditionary Education, Advisory and Athletic programs, and Community Service.
-
Senior Director - R&D And Research OperationsHalozyme Therapeutics, Inc. Dec 2008 - May 2010San Diego, CaResearch Operations; Preclinical Development; IND and NDA submissions; Discovery Research and R&D program tracking and timetable management; RA/QA and Regulatory Affairs/Operations liaison; Budget forecasting and tracking; Grants and Contracts (USG, public, and private agencies) opportunity identification, proposal writing and submissions; Management of External Collaborations: identifying, initiating, timeline and milestone tracking and reporting of collaborative activities (Academic, Industry, Contract Research: CDA, MTA, MRA, SOW, and MSA agreements, R&D planning, project management); identifying, initiating and managing external R&D programs at CROs (contract research organizations: non-clinical, toxicology); patent capture and extension; strategic alliances and business development; scientific liaison across departmental lines in a matrix-based R&D organization. -
PrincipalBiopharma Services, Llp Feb 2008 - Dec 2008San Diego, CaWe provide strategic consulting to the biotechnology and pharmaceutical industry, including: Preclinical pharmacology and toxicology planning; CRO engagement and due diligence; Business development and scientific planning; Angel, VC and corporate venture fundraising; Business plan development; In- and out-licensing of technologies/IP; Due diligence including legal/IP/freedom to operate; Product development strategies; Writing grants and contracts submitted to public and private funding agencies for non-dilutive financing; and technical consultation for private biotechnology companies. Recent CLIENTS include: EpiVax, Inc., Immunex/Amgen, Genentech/Roche, Merck, Inc., Schering, AG, Multimeric Biotherapeutics, Inc., Cardium Therapeutics, Inc. Recent PROJECTS include: cancer immunotherapeutics, protein- and nucleotide-based therapeutic product development; immunogenicity screening; preventative and therapeutic vaccines and adjuvant development; antigen discovery; and preclinical pharmacology and toxicology program development.
-
Senior Vice President - R&DCoda Genomics, Inc. (Now Verdezyne, Inc.) Mar 2006 - Jan 2008Laguna Nigel, CaCODA Genomics is a synthetic biology-based biotechnology company spun out of UC-Irvine Depts of Microbiology and Molecular Genetics (School of Medicine), and Computer Sciences. I was responsible for creating and developing applications for CODA’s gene design and protein optimization products and technologies pipeline, developing and managing the intellectual property portfolio, and creating and maintaining strategic business and academic collaborations for grants, alliances, and strategic relationships. I worked closely with CODA’s Business and Market Development, Operations, and Sales and Marketing teams to conceive, propose, execute, and manage corporate funded partnerships related to CODA’s technologies and their applications. I managed all interactions with CODA’s Scientific Advisory Board, and worked closely with the company founders, CODA’s Board of Directors, and patent and corporate attorneys to develop new applications of the CODA’s technologies, including engineered enzymes for biofuel synthesis. Using these grant-backed enzymes CODA has now become Verdezyne, Inc., focusing on renewable biofuels.
-
Advisor And Mentor (Volunteer)Resounding Joy Feb 2004 - Mar 2007Resounding Joy is a public-benefit, California non-profit 501c3 corporation, dedicated to providing a supportive and healing music environment to adults and children who are homebound or have special needs. Resounding Joy accepts referrals from individuals and community-based organizations who want to offer recreational music-making programs hospital-bound children through rest/retirement home-bound older adults. Resounding Joy trains volunteer Joy Givers to bring words and sounds of hope, encouragement and appreciation for the joy and consolation brought by music. It has been shown in countless small and large group venues that Music is Therapy.
-
Vice President - R&DGene Therapy Systems, Inc. (Gts) Jan 2003 - Mar 2006• Developed Vaccinomics (TM/SM), a high throughput antigen discovery platform for development of protective and therapeutic vaccines and diagnostics. • Identified and executed on new funding opportunities including VC, new business alliances and partnerships, technology licensing and therapeutic applications of platform technologies.• Spearheaded and wrote successful SBIR and STTR grants and contract applications.• Business Development: identified and negotiated strategic alliances and partnerships with vaccine and diagnostic companies, US government, and non-profit organizations. • Identified and evaluated novel gene- and protein-based technologies for the product pipeline through licensing deals with Technology Transfer Offices at academic and research institutions.• Designed and oversaw the development of new products.• Wrote new patent applications for novel products invented in-house. • Created and directed collaborations and partnerships with biotechnology, vaccine and diagnostic companies, academic and institutional collaborations, and scientific consultants/SAB.
-
Director Of Research And TechnologyCollateral Therapeutics, Inc. Jul 1998 - Dec 2002• Directed all preclinical activities of the R&D group, including in vivo and in vitro work in a variety of animal models and cell-based and viral vector systems, and development of new catheter-based and cardiovascular imaging systems.• Managed the work of 25 scientists: cell and molecular biology, biochemistry, rodent and large animal physiology/pharmacology, and process development. • Created, implemented, and directed internal research and development programs and collaborative R&D projects. • Directed and coordinated internal interactions between R&D, program management, quality assurance, regulatory affairs, legal counsel (patents, licensing, IP), process development and manufacturing (GLP, GMP, QA/QC), pre-clinical and clinical development, HR, financial planning and budgets.• Directed and reported interactions between Collateral and industrial alliances, academia, scientific consultants, CROs and CSOs, the FDA (Center for Biologics and Evaluation Research – CBER), and the Recombinant DNA Advisory Committee (RAC) at the NIH.• Leadership during evaluation and prioritization of programs and projects during acquisition/transition phases of Collateral with Schering, AG-Berlex Biosciences.
-
Key Word SearchKey Words Jan 1998 - Dec 1998Keywords Key Word Search(Privately Held; Biotechnology industry)January 1976 — January 1977 (1 year 1 month) Cardiovascular, CV, angiogenesis, peripheral vascular disease, PVD, catheter, Diabetes, T1DM, T2DM, insulin, hyaluronidase, rHuPH20, streptozotocin, protein biologics, DNA, RNA, RNAi, miRNA, vaccines, diagnostics, infectious disease, antibody, Ab, MAb, mAb, antigen, Ag, receptor, ligand, biotherapeutics, adjuvants, grants, contracts, USG, ADA, DOD, DOE, NIH, SBIR, STTR, NMRC, CDC, WHO, strategic stockpiling, co-development, research, R&D, development, business development, BD, Alliance Management, cGMP, strategic alliances, Professional Relations, Advocacy Development, program management, project management, Vice President, VP, Senior Vice President, SVP, Senior Director, Director, gene therapy, viral, vectors, cancer, immunology, melanoma, skin cancer, lymphoma, NSCLC, T-Cell, lung cancer, non-small cell, ovarian, breast cancer, IND, NDA, DEA, infusion products, new product development, vendor management, agency management, executive management, senior management, providers, advocacy, society, SC, subcutaneous, IV, intravenous, IC, intracoronary, ID, intradermal, biosimilars, preclinical, pre-clinical, non clinical, non-clinical, nonclinical, enabling, platform technologies, consultant, consulting, SAB, mentor.
-
Assistant ProfessorUniv. Of Colorado-Boulder Aug 1992 - Jul 1998Tenure-track with research (40%), teaching (40%), and service (20%):• Research: successful and consistent intramural & extramural grant funding for basic and applied research and student training fellowships (American Heart Assn, American Fed for Aging Res, Howard Hughes Biomedical Research Foundation (UROP); fostered academic and industry collaborations. • Teaching: undergraduate (Physiology lecture/labs and seminars) and graduate (Biochemistry and Molecular Endocrinology lecture/labs and seminars). • Service: national, state, community, and university-wide committees.Winner: Teaching Excellence Award, CU-Boulder Student Organization for Alumni Relations. Award for tenure track faculty (~1,100 eligible) for the 30-75 undergraduate student class size. April, 1998 Biomedical Research Award - 1993American Federation of Aging Research (AFAR)Finalist: Faculty Excellence in Research, Scholarly, and Creative Work Award.Boulder Faculty Assembly, CU-Boulder. May 1995.
David A. Roth, Ph.D. Skills
David A. Roth, Ph.D. Education Details
-
Pre-Med; Physiology; Biochemistry -
Taught: Undergraduates, Graduates And Postdoctoral Fellows -
Molecular Cardiology -
Albuquerque Academy - Independent High School
Frequently Asked Questions about David A. Roth, Ph.D.
What company does David A. Roth, Ph.D. work for?
David A. Roth, Ph.D. works for Multimeric Biotherapeutics, Inc.
What is David A. Roth, Ph.D.'s role at the current company?
David A. Roth, Ph.D.'s current role is Chief Operating Officer at Multimeric Biotherapeutics, Inc..
What is David A. Roth, Ph.D.'s email address?
David A. Roth, Ph.D.'s email address is da****@****ail.com
What is David A. Roth, Ph.D.'s direct phone number?
David A. Roth, Ph.D.'s direct phone number is +185834*****
What schools did David A. Roth, Ph.D. attend?
David A. Roth, Ph.D. attended University Of California, Berkeley, University Of Colorado At Boulder, Uc San Diego School Of Medicine, Albuquerque Academy - Independent High School.
What skills is David A. Roth, Ph.D. known for?
David A. Roth, Ph.D. has skills like Biotechnology, Technology Transfer, Biopharmaceuticals, Immunology, Drug Development, Patents, Technology Evaluation, Life Sciences, Cell, Pharmaceutical Industry, Biochemistry, Lifesciences.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial